Association between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: A meta-analysis

Gene

Volumn 528, Issue 2, 2013, Pages 328-334

  Wang, Jun ^a   Guo, Xufeng ^a   Wu, Pengbo ^a   Song, Jia ^a   Ye, Chuncui ^a   Yu, Shijie ^a   Zhang, Jixiang ^a   Dong, Weiguo ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Meta analysis; Non alcoholic fatty liver disease; Polymorphism; PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; POPULATION GENETICS; PRIORITY JOURNAL; RISK ASSESSMENT;

CI; CONFIDENCE INTERVAL; HARDY-WEINBERG EQUILIBRIUM; HWE; META-ANALYSIS; METABOLIC SYNDROME; MS; NAFLD; NASH; NON-ALCOHOLIC FATTY LIVER DISEASE; NON-ALCOHOLIC STEATOHEPATITIS; ODDS RATIO; OR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-Γ; POLYMORPHISM; PPAR-Γ; SINGLE NUCLEOTIDE POLYMORPHISM; SNP;

AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; FATTY LIVER; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 84883054625     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.07.014     Document Type: Article

References (35)

1. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease. CMAJ 2005, 172:899-905.
2. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346:1221-1231.
3. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
4. Bhatt S.P., et al. Association of peroxisome proliferator activated receptor-γ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. Gene 2013, 512:143-147.
5. Boccia S., De Feo E., Gallì P., Gianfagna F., Amore R., Ricciardi G. A systematic review evaluating the methodological aspects of meta-analyses of genetic association studies in cancer research. Eur. J. Epidemiol. 2010, 25:765-775.
6. Cao C.Y., et al. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J. Exp. Med. 2012, 227:253-262.
7. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
8. Di Rosa M., Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J. Mol. Med. (Berl.) 2012, 90:105-118.
9. Dongiovanni P., et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2010, 10:102.
10. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
11. Gawrieh S., et al. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig. Dis. Sci. 2012, 57:952-957.
12. Gouda H.N., Sagoo G.S., Harding A.H., Yates J., Sandhu M.S., Higgins J.P. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am. J. Epidemiol. 2010, 171:645-655.
13. Gupta A.C., et al. Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol. Int. 2010, 5:575-580.
14. Kallwitz E.R., McLachlan A., Cotler S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 2008, 14:22-28.
15. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 1997, 127:820-826.
16. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 2008, 28:339-350.
17. Lu Y.L., et al. Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis. World J. Gastroenterol. 2010, 16:2170-2175.
18. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
19. Mendez-Sanchez N., et al. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007, 27:423-433.
20. Paracchini V., Pedotti P., Taioli E. Genetics of leptin and obesity: a HuGE review. Am. J. Epidemiol. 2005, 162:101-114.
21. Rey J.W., et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases. World J. Gastroenterol. 2010, 16:5830-5837.
22. Romeo S., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
23. Stickel F., Hampe J. Genetic determinants of alcoholic liver disease. Gut 2012, 61:150-159.
24. Stumvoll M., Haring H. The peroxisome proliferator activated receptor 2 pro12ala polymorphism. Diabetes 2002, 51:2341-2347.
25. Tang S.T., et al. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: a meta-analysis. Mol. Biol. Rep. 2012, 39:9649-9660.
26. Valenti L., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148 M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
27. Wang Y., Liu C. Quantitative evaluation of common polymorphism (rs1801282) in the PPARγ2 gene and hypertension susceptibility. Gene 2012, 502:159-162.
28. Wang J.K., et al. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J. Gastroenterol. Hepatol. 2012, 27:670-676.
29. Xu W., et al. PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol. Rep. 2010, 24:579-585.
30. Yang Z., et al. PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Mol. Cell. Endocrinol. 2012, 348:255-259.
31. Ye Q., Lv Z.S. A study of the association between PPARγ2 gene Pro12Ala polymorphism and NAFLD. Zhonghua Gan Zang Bing Za Zhi 2007, 15:228-229. (Article in Chinese).
32. Yen C.J., et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997, 241:270-274.
33. Zhang H., et al. Association between the Pro12Ala polymorphism of PPAR-γ gene and the polycystic ovary syndrome: a meta-analysis of case-control studies. Gene 2012, 503:12-17.
34. Zhang H., et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012, 35:1388-1393.
35. Zhang Z.F., et al. Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis. PLoS One 2012, 7:e30551.